Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells $393,853.40 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ultragenyx Pharmaceutical Stock Up 2.3 %

RARE stock opened at $55.10 on Monday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $31.52 and a 52-week high of $60.37. The stock’s 50 day moving average is $55.06 and its two-hundred day moving average is $47.22. The company has a market capitalization of $4.58 billion, a PE ratio of -6.86 and a beta of 0.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.12. The company had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 35.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.25) EPS. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. UMB Bank n.a. grew its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 352 shares in the last quarter. US Bancorp DE grew its position in shares of Ultragenyx Pharmaceutical by 5.8% in the 1st quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 390 shares in the last quarter. Arizona State Retirement System grew its position in shares of Ultragenyx Pharmaceutical by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 434 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Ultragenyx Pharmaceutical by 8.7% in the 1st quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock worth $284,000 after acquiring an additional 486 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $28,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 1st. Wells Fargo & Company raised their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada reissued an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th. Canaccord Genuity Group reissued a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Finally, Wedbush raised their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $87.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.